Market reactionShares rose 15% on Nov 4.
Palatin Technologies is a clinical-stage company developing melanocortin receptor drugs, led by MC4R agonists for obesity and rare obesity disorders; it no longer owns an approved product.
Palatin's case now rests on two MC4R agonist programs for obesity and rare disorders, with Phase 1 trials projected for 2027. It has licensed out or sold several other assets, and fiscal 2026 revenue of $13.2 million came from the Boehringer Ingelheim and Altanispac agreements. Cash was $7.5 million at June 30, 2026, and Palatin reports substantial doubt about continuing as a going concern, with no committed financing.
Thesis checklist
1 risk needs attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: Palatin raises money to reach its first MC4R trials
Can Palatin fund operations into its 2027 Phase 1 trials?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Palatin reports going-concern doubt with $7.5 million in cash as it prepares its first MC4R obesity trials for 2027
Palatin's pre-IND oral MC4R agonist faces a long road to proof-of-concept in obesity and rare disorders against a field dominated by approved GLP-1 agents
Boehringer Ingelheim partnership for melanocortin receptor agonist in retinal diseases
NYSE American delisting notice; transition to OTC Pink
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Eye diseases, Kidney diseases, Neurology and pain, Liver and digestive diseases, Obesity, diabetes and heart disease, Rare genetic and metabolic diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
14 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.